HIMS & HERS HEALTH INCHIMS
ASignal's systematic analysis rates HIMS as Neutral.
Reflects the latest available analysis · analyzed Oct 10, 2026
The case on HIMS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (38.2% YoY)
- High gross margin (69.53%) indicating pricing power
- Positive free cash flow ($849.44M)
- MACD histogram expanding above signal line suggesting bullish momentum
- Price above 20-day and 50-day moving averages
- Negative operating margin (-12.75%)
- Negative return on equity (-32.03%)
- High debt-to-equity ratio (4.77x)
- Current ratio below 1.0 (0.93x) indicating liquidity concerns
- EV/EBITDA negative at -712.58x
- Forward P/E of 41.94x above growth rate, suggesting overvaluation
See the full verdict on HIMS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes HIMS
Most investors never get a second opinion, let alone several. ASignal runs HIMS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.